NR1H4 and metabolic dysfunction-associated steatohepatitis: Several FXR agonists are being combined with other agents, including cenicriviroc, a CCR2/CCR5 inhibitor [94], or firsocostat, an acetyl-CoA carboxylase inhibitor, to treat MASH [95, 96].